In the News

Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial

Gateway for Cancer Research accelerates practice-changing clinical trials to cancer research by harnessing the unrelenting passion of the research community and empowering patients to triumph over their disease. All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.

Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets

Balstilimab and botensilimab combination therapy showed superior efficacy in MSS mCRC patients without liver metastases compared to botensilimab monotherapy.

Redefining Cancer Care

Harnessing the power of the immune system, Agenus Bio leads the charge in immuno-oncology.

I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer

The new issue of OncoDaily Magazine had the privilege to feature an exclusive interview with Dr. Benny Johnson, Senior Medical Director at Agenus, discussing his career and dedication to oncology, his motivation, professional vision for emerging treatments and personal experiences with cancer.

Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status

Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.

Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer

Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting.

Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200